Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

    Best Selling Products

    BioNewsCast Press Release Distribution Service

    BioNewsCast Press Release Distribution Service

     

    3rd Annual Stability Testing Conference

    3rd Annual Stability Testing Conference

     

    Next-Gen Sequencing Trends 2009

    Next-Gen Sequencing Trends 2009

     

    Competitor Analysis: c-MET/HGF Inhibitors

    Competitor Analysis: c-MET/HGF Inhibitors

     

    The Japanese Pharmaceutical Market 2008-2023

    The Japanese Pharmaceutical Market 2008-2023

     

    New Products

    Japanese Pharmaceutical Market 2009-2024

    Japanese Pharmaceutical Market 2009-2024

     

    3rd Annual Lyophilisation Conference

    3rd Annual Lyophilisation Conference

     

    The Global Bioinformatics Market: Market size, forecasts and company profiles

    The Global Bioinformatics Market: Market size, forecasts and company profiles

     

    Pharmaceutical Mergers and Acquisitions (PH133)

    Pharmaceutical Mergers and Acquisitions (PH133)

     

    Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

    Pharmaceutical Speaker Programs (PH134) Measuring ROI and Communicating Value

     

    Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

    Strategic Clinical Sourcing (PH125)) Managing Costs and CROs

     

    The Global Analgesics Market 2009-2024

    The Global Analgesics Market 2009-2024

     

    Competitor Analysis: Coagulation Factors

    Competitor Analysis: Coagulation Factors

     

    Competitor Analysis: PDGF-R Agonists and Antagonists

    Competitor Analysis: PDGF-R Agonists and Antagonists

     

    World Market for Addiction Disorders, 2009-2016

    World Market for Addiction Disorders, 2009-2016

     

    BioPortfolio | Medtech Ventures |  Drug Eluting Coronary Stents Market - Current Situation & Future Outlook

    Drug Eluting Coronary Stents Market - Current Situation & Future Outlook

    Drug Eluting Coronary Stents Market - Current Situation & Future Outlook


    The Market for Drug Eluting Coronary Stents grew by 3% in 2008 reaching $4.2 Billion globally. Decline in average selling price was offset by growth in procedure volume and improved penetration levels.

    The US market remained stable at $1.8 billion accounting for 43% of the world market. The launch of Medtronic's Endeavor zotarolimus-eluting stent and Abbott's & Boston Scientific's Xience and Promus everolimus-eluting stents during the year, redistributed market shares with JnJ's Cypher losing the most.

    The market for drug eluting coronary stents is exhibiting clear evidence of recovery with average annual PCI volumes rising by 5% in the US and 4% in Europe. Average penetration rates are also rising in all markets.

    Drug Eluting Coronary Stents Market - Current Situation & Future Outlook is a New 2009 Edition of Medtech Ventures' best selling report. The report offers a timely analysis of the latest happenings with market revenue and growth rates for main regions, up-to-date market shares for leading companies and brands and market forecasts to 2015.

    With Drug Eluting Coronary Stents Market - Current Situation & Future Outlook, you'll be able to:

    Understand current market dynamics, competitor positions and market shares.

    Assess market size and growth potential for these combined drug devices.

    Monitor the competition's marketed and in-development products.

    Identify emerging technologies and the companies behind them.

    Assess market potential and have access to forecasts till 2015.

    Leverage your own technology and brain storm new business opportunities.

    Investigate mergers, acquisitions and licensing possibilities

    Report Code: MV09023

    Report Publisher: Medtech Ventures

    Date Published: February 2009

    Number of Pages: 40

    Report Price:

    PDF file by email: $2,450

    Site License: $4,900


    View Table of Contents...

    Price
    PDF Single User $2450.00   
    PDF Site Licence $4900.00   



    BioPortfolio uses RBS Worldpay Secure Server for credit card transactions